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            Over the past two decades, breakthroughs in basic science have revealed the genetic 
etiology for several inherited arrhythmias.  Onset of arrhythmias often commences in childhood 
and adolescence.   The aim of the article is to provide a succinct overview of the genetic 
background of diseases that may cause life threatening arrhythmias in children and provide a 
description of reported genotype-phenotype relationships.  Inherited channelopathies, namely, 
those causing long QT syndrome, short QT syndrome, catecholamine sensitive ventricular 
polymorphic   ventricular   tachycardia   and   Brugada   syndrome   and   two   cardiomyopathies 
(hypertrophic   and  arrhythmogenic   right  ventricular  dysplasia)   associated   with  ventricular 
arrhythmias  are discussed.                                                                                     
Inherited   Channelopathies                                                                                    
The  Long   QT  Syndrome                                                                                   
            The Long QT syndrome (LQTS) is an inherited arrhythmogenic disease occurring in the 
structurally normal heart that may cause sudden death and that usually manifests in children and 
teen-agers1. The estimated prevalence of this disorder is between 1:2,500 and 1:1,500.  Two 
major phenotypic variants have been originally described in the early sixties: one autosomal 
dominant (Romano Ward syndrome) and one rare autosomal recessive (Jervell and Lange-
Nielsen syndrome) also presenting with sensorineural deafness2.                                                 
               The LQTS is caused by an abnormal cardiac excitability. As a result, the affected 
patients have prolonged repolarization (QT interval at the surface electrocardiogram), abnormal 
T wave morphology, and life threatening cardiac arrhythmias. The mean age of onset of 
symptoms (syncope or sudden death) is 12 years and earlier onset is usually associated with 
more severe form of the disease3.  Cardiac events are often precipitated by physical or emotional 
stress even though in a smaller subset of individuals cardiac events occur at rest4. For this reason 
antiadrenergic intervention with beta blockers is the cornerstone of therapy in the LQTS. For 
patients unresponsive to this approach, ICD and/or cardiac sympathetic denervation were 
proposed.   It has been recently demonstrated that the response to beta blocker therapy is 
significantly modulated by the genotype and, specifically, the protection afforded by this 
approach is only partial for LQT2 and LQT3 patients5,6.                                         
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Genetic Basis of Long QT Syndrome                                                                                     
            As of today 10 LQTS genes have been identified.  The typical LQTS phenotype with or 
without deafness may be due to mutations in 5 different genes while two variants present QT 
interval prolongation in the context of a multi-organ disease (Andersen syndrome) or with 
peculiar electrocardiographic features (LQT4).   The discovery of the genetic basis of LQTS 
started in the early nineties with the mapping of four LQTS loci on chromosomes 11, 3, 7 and 4.  
The genes for these loci have been subsequently identified as KCNQ1 (LQT1) KCNH2 (LQT2) 
and SCN5A (LQT3),7-9.  More recently mutations in two additional genes on chromosome 21, 
KCNE1 (LQT5) and KCNE2 (LQT6) were reported.  All the LQT1-3 and LQT5-6 genes encode 
for cardiac ion channels subunits. LQT4 is caused by mutations in the ANK2 genes that encodes 
an intracellular protein called Ankyrin B that is involved in ion channels anchoring to the 
cellular membrane10.                                                                                                                         
LQT1, LQT5, JLN1, JLN2: KCNQ1 (causing LQT1 and JLN1) and KCNE1 (causing LQT5 and 
JLN2) encode respectively for the alpha (KvLQT1) and the beta (MinK) subunits of the 
potassium channel conducting the IKs current, the slow component of the delayed rectifier 
current (IK) the major repolarizing current during phase 3 of the cardiac action potential.  In 
order to form a functional channel, KvLQT1 proteins form homotetramers and it must also co-
assemble with mink subunits.                                                                                                           
            LQT1 is the most prevalent genetic form of LQTS accounting for approximately 50% of 
genotyped patients. Several different mutations have been reported and in vitro expression 
studies of mutated proteins suggested multiple biophysical consequences all of them ultimately 
inducing a loss of function.  Homozygous or compound heterozygous mutations of KCNQ1 also 
cause Jervell and Lange-Nielsen form of LQTS (JLN1)2.  KCNE1 (LQT5) mutations are rather 
infrequent accounting approximately of 2-3% of genotyped LQTS patients and they may cause 
both Romano-Ward (LQT5)  and, if homozygous,  Jervell and Lange-Nielsen  (JLN2)11,12.
            From a clinical standpoint LQT1 patients are those presenting a more straightforward 
adrenergic trigger for cardiac events. LQT1 is also characterized by the lower penetrance and a 
more benign prognosis compared with LQT2 and LQT313.                                        
LQT2, LQT6: KCNH2 (LQT2) and KCNE2 (causing LQT6) gene encode respectively for the 
alpha (HERG) and the beta (MiRP) subunits of the potassium channel conducting the IKr 
current the rapid component of the cardiac delayed rectifier.  The KCNH2 encoded protein, 
HERG, forms homotetramers in the plasmalemma in order to make up functional channels8.  
The role or MiRP protein to recapitulate a fully operational current has been postulated but 
questioned by other authors.  LQT2 is the second most common variant of LQTS accounting for 
35%-40%   of   mutations.   Functional   expression   studies   have   demonstrated   that   KCNH2 
mutations cause a reduction of IKr current, but, similarly to LQT1 mutations, this effect is 
realized through different biophysical mechanisms and also though trafficking abnormalities of 
the mutant proteins10. LQT2 is characterized by higher penetrance and severity than LQT1, 
especially for females13. Mutations in the KCNE2 gene cause the LQT6 variant of LQTS, which 
is   a   very   uncommon   variant   of   the   disease   (<1%)   and   the   associated   phenotypes   are 
characterized by incomplete penetrance and very mild manifestations.                        
SCN5A (LQT3): SCN5A encodes for cardiac sodium channel conducting the sodium inward 
current (INa). At variance with KvLQT1 and HERG proteins mutation, a single SCN5A 
transcript forms a fully functional channel protein (called Nav1.5).  The first reported SCN5A 
mutations   were   clustered   in   regions   functionally   associated   with   channel   inactivation. 
Subsequently several allelic variants have been reported and functional expression studies 
showed that, at variance with LQT1 and LQT2-asociated mutations, LQT3 defects cause a gain 
of function with an increased INa9. The prevalence of LQT3 among LQTS patient is estimated 
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to be 10-15%, it is probably the more malignant form of LQTS and the one in which beta-
blockers   are   less   effective13.                                                                            
ANK2 (LQT4): The phenotype of the LQT4 patients differs from the typical LQTS. Most of the 
affected   individuals,   besides,   QT   interval   prolongation,   also   present   with   severe   sinus 
bradycardia,   paroxysmal   atrial   fibrillation   (detected   in   >50%   of   the   patients)   and   with 
polyphasic T waves14.  ANK2 encodes for an intracellular protein (Ankyrin B) that regulates the 
proper intracellular localization of plasmalemmal  ion channels (calcium channel, sodium 
channel, sodium/calcium exchanger), sarcoplasmic reticulum channels (ryanodine receptor, 
inositol triphosphate receptor), and other adhesion molecules. The low number of LQT4 patients 
genotyped so far prevents the definition of prevalence (which appears low) and phenotypic 
features of this variant of LQTS. Additional ANKB mutations have been reported in patients 
with different forms of cardiac rhythm disturbances, thus further supporting the important role of 
this protein in the pathogenesis of cardiac arrhythmias10.                                         
KCNJ2 (LQT7- Andersen syndrome): In 2001, this disease was successfully mapped to the locus 
17q in a large family.  A candidate gene screening was carried out in the critical region and a 
heterozygous missense mutation was identified in the KCNJ2 gene.  Additional mutations were 
subsequently identified in 8 unrelated individuals, thus providing the proof that KCNJ2 is the 
cause of at least some of AS.  KCNJ2 encodes an inwardly rectifier potassium channel, Kir2.1, 
the ionic channel conducting the IK1 current.  It is highly expressed in the heart where it appears 
to act as a determinant factor of phase 4 repolarization and of resting membrane potential. 
Interestingly, since dysmorphic facial appearance constitutes a distinctive trait of AS, the data 
also strongly suggest that Kir2.1 plays a major role in developmental signaling. Severe, 
functional impairment of IK1 current has been observed for all AS mutations so far studied with 
a variable degree of dominant negative effect when co-expression with wild type subunit10. 
CACNA1c (LQT8 - Timothy syndrome):  Molecular screening of several cardiac ion channel 
encoding genes allowed the identification of a missense mutation (G406R) in the voltage-gated 
calcium channel gene (CACNA1c)15.   Interestingly the same mutation was present in all 
probands analyzed and in one case parental mosaicism was demonstrated. Functional expression 
revealed that the G406R mutation produced maintained inward Ca(2+) currents by causing 
nearly complete loss of voltage-dependent inactivation. In the heart, prolonged Ca(2+) current 
delays cardiomyocyte repolarization and increases risk of arrhythmia.   In other tissues and 
during fetal development this mutation is likely to cause intracellular calcium overload, a well 
known mechanism of tissue damage.                                                                                     
CAV3 (LQT9): Mutations in CAV3 that encodes for caveolin 3 have been linked to a rare form 
of long QT syndrome designated as LQT9 which has been also been associated with sudden 
infant death syndrome (SIDS)16.                                                                                 
SCNB4 (LQT10):  Mutations in SCNB4 are responsible for another rare type of long QT 
syndrome designated as LQT1017.                                                                             
Genotype-Phenotype Correlation in Long QT Syndrome                                     
            In the last few years several studies have outlined the distinguishing features of the three 
most   common   genetic   variants   of   LQTS   (LQT1,   LQT2,   LQT3),   which   account   for 
approximately 97% of all genotyped patients. Gene-specific repolarization morphology and 
gene-specific triggers for cardiac events have been described. LQT1 patients usually develop 
symptoms during physical activity, conversely LQT3 have events at rest. Auditory stimuli and 
arousal are a relatively specific trigger for LQT2 patients while swimming is a predisposing 
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setting for cardiac events in LQT1 patients3. Gene-specific differences of the natural history of 
LQTS have also been demonstrated and allow genotype-based risk stratification13. Indeed, QT 
interval duration, genotype and gender are significantly associated with the outcome with a QTc 
interval >500ms, and a LQT2 or LQT3 genotype determining the worst prognosis. Gender 
differentially modulates the outcome according to the underlying genetic defect: the LQT3 
males and LQT2 females are the highest risk subgroups. LQT8 is a rare variant of LQTS 
characterized  by marked  QT interval  prolongation  (often presenting  with  2:1 functional 
atrioventricular block and macroscopic T wave alternans), and cutaneus syndactyly at both 
hands and feet.  Severe prognosis has been observed in all cases described so far15. Individuals 
with Timothy syndrome (TS) also had congenital heart disease, including patent ductus 
arteriosus, patent foramen ovale, ventricular septal defects, and tetralogy of Fallot. Some 
children had dysmorphic facial features, including flat nasal bridge, small upper jaw, low-set 
ears, or small or misplaced teeth. Episodic serum hypocalcemia was described in 4 individuals. 
Many of the surviving children showed developmental delays consistent with language, motor, 
and generalized cognitive impairment. The definition of Andersen syndrome (AS) was used for 
the first time in 1994 by Tawil et al to describe a clinical disorder consisting of three major 
features: potassium-sensitive periodic paralysis, ventricular arrhythmias and dysmorphic features 
(short stature, hypertelorism, broad nasal root, and defect of soft and hard palate). An additional 
peculiar feature of AS is the presence of a variable degree of QT interval prolongation and 
abnormal T wave morphology often presenting with very prominent U waves. Life threatening 
ventricular arrhythmias are probably rare in AS although sudden death has been reported.
Short   QT   Syndrome                                                                                      
            The first report of the so-called "short QT syndrome" (SQTS) was provided by Gussak et 
al.   who  described   a  familial   distribution   of  a  persistently  short  QT  interval   associated 
paroxysmal atrial fibrillation in one patient18. They also reported similar ECG changes in an 
unrelated case associated with sudden cardiac death. More recently, these observation have been 
refined by Gaita et al. who described two families with severe history of sudden cardiac death, 
QTc interval constantly below 290ms, ventricular premature beats and documented ventricular 
fibrillation19.  
            SQTS is also characterized by the absence of structural heart disease, a remarkable 
familial history of sudden cardiac death and a typical, hyperkalemic-like T wave pattern (tall and 
peak T wave) with a very fast terminal phase of repolarization on the resting ECG. ICD 
implantation is currently the treatment of choice for symptomatic patients with short QT 
syndrome and a family history of sudden cardiac death.  Quindine has been shown to normalize 
ventricular repolarization (at variance with other antiarrhythmic drugs including sotalol and 
amiodarone) in some patients but at present its role in preventing recurrences of cardiac events is 
not known. Therefore, at present this approach may not be considered an alternative to ICD. 
Genetic background of short QT syndrome                                                                   
            The prevalence of the SQTS is currently unknown and less than 50 families have been 
reported.   In the two families reported by Gaita et al., genetic investigation led to the 
identification of a coding defect in the KCNH2 gene19. In vitro functional characterization 
demonstrated a remarkable increase of IKr current, and reduced the affinity of the channels to 
IKr blockers20. Thus, it is suggested that, at variance with the LQT2 variant of Long QT 
Syndrome associated with loss of function KCNH2 mutation, the SQTS phenotype is caused by 
gain of function mutations.   More recently, Bellocq et al. reported another sporadic case of 
SQTS with a missense mutation of the KCNQ1 gene.  In vitro expression demonstrated a gain of 
function with an increase of the IKs current.  In March 2005 Priori et al. identified a novel SQTS 
locus (SQTS3) by reporting a gain of function mutation in the KCNJ2 gene, encoding the inward 
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rectifier potassium channel which is a voltage-gated channel responsible for the IK1 current21.
            Thus, SQTS is a genetically heterogeneous disease. Genotype-phenotype correlation and 
clinical data on natural history, risk stratification and optimal therapeutic management are still 
lacking.  
Catecholaminergic polymorphic ventricular tachycardia                                                                 
               Catecholaminergic   polymorphic   ventricular   tachycardia   (CPVT)   is   a   familial 
arrhythmogenic disorder characterized by adrenergically mediated polymorphic ventricular 
tachyarrhythmias22. It is an important cause of syncope and sudden cardiac death in individuals 
with a structurally normal heart and usually a normal QT interval on the surface ECG.  If left 
untreated, 80% of patients will develop symptoms by the age of 40 years and the overall 
mortality   is   30-50%  23.                                                                                  
Genetic background of catecholaminergic polymorphic ventricular tachycardia                        
            Recently, genetic investigations have identified two variants of the disease: an autosomal 
dominant form associated with mutations in the gene encoding the cardiac ryanodine receptor 
(RyR2) and a recessive form associated with homozygous mutations in the gene encoding the 
cardiac isoform of calsequestrin (CASQ2). The first advancement in the understanding of the 
pathophysiology of CPVT was made possible by the linkage studies that were able to localize 
the CPVT locus to the long arm of chromosome 1 (1q42–q43). Subsequently, Priori and 
coworkers using the candidate gene approach screened the open reading frame of the RyR2 gene 
encoding the cardiac RyR2 and identified pathogenic mutations in four CPVT probands24. RyR2 
is a protein functionally involved in the Ca2+  release from the sarcoplasmic reticulum in 
response to the activation of the ICa2+ current through the dihydropyridine receptor during the 
plateau phase of the action potential. The clear adrenergic-mediated onset of arrhythmias closely 
resembles  the arrhythmias   developing  during  intracellular  calcium  overload  and  delayed 
afterdepolarization. A few years later, advancement in the study of CPVT was obtained when 
the autosomal recessive variant of CPVT was linked to chromosome 1 (1p13–p21) and 
established that the disease gene is encoding for cardiac calsequestrin (CASQ2), another protein 
strictly implicated in the control of intracellular calcium25.                                    
            Taken together the experimental data demonstrated that both genes involved in CPVT 
pathogenesis affect the amount of Ca2+ released from the SR during adrenergic stimulation. Such 
effect may create an electrically unstable substrate probably through triggered activity-mediated 
arrhythmogenesis.
Brugada   Syndrome                                                                    
            Brugada syndrome (BrS) is an inherited arrhythmogenic disease characterized by ST 
segment elevation in the right precordial leads (V1 to V3), right bundle branch block (either 
complete and incomplete) and susceptibility to ventricular tachyarrhythmia, typically during rest 
or sleep26. Supraventricular tachyarrhythmias like atrial fibrillation are also a common finding in 
these   patients.                                                                        
            Brugada syndrome is inherited as autosomal dominant trait, but the majority of the 
individuals developing ventricular arrhythmias are of male gender (male to female ratio: 8:1).  
Furthermore, despite the genetic defect is present since birth the disease tends to manifest in the 
third decade of life. Indeed, syncope or cardiac arrests occur more often in the third to fourth 
decade of life. Only rare instances of malignant forms with earlier onset during childhood or 
neonatal manifestations have been reported. The causes of age- and gender- related penetrance 
of   BS   are   unclear.                                                                                      
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Genetic background of Brugada syndrome                                                                     
            Mutations in the cardiac sodium channel gene, SCN5A, on chromosome 3p21-23, have 
been identified for the first time in 1998. This gene encodes for the alpha subunit of the cardiac 
sodium   channel   protein   (identified   as   Nav1,5),   which   is   the   most   important   player   in 
determining the phase 0 of the cardiac action potential (depolarization), thus it controls a crucial 
step in the physiology of electrical activation of the heart27. Interestingly, BrS is not the only 
phenotype linked to SCN5A mutations.  Known allelic disorders are: the LQT3 variant of Long 
QT syndrome, the progressive cardiac conduction defect and the sick sinus syndrome28. 
Furthermore, recent findings also suggest that SCN5A mutations may be present in patients with 
typical BrS electrocardiogram but also myocardial abnormalities resembling those typical for 
arrhythmogenic   right   ventricular   cardiomyopathy   (ARVC)   and   in   families   with   dilated 
cardiomyopathy (DCM)10. SCN5A has a 6.048 Kb coding sequence spanning and approximately 
65% of mutations so far reported in this gene are associated with a BrS phenotype but no 
specific clustering within the coding region is demonstrable. Interestingly, not only ORF 
mutations but also genetic variants in the SCN5A promoter may have pathophysiologic role in 
BrS. A haplotype block of six SNP in the SCN5A promoter has been identified and functionally 
linked to a reduced expression of the sodium current. This variant was found among subjects of 
Asian origin (allelic frequency 0.22) and it could play a role in modulating the expression of BrS 
in far east countries where the disease is thought to be particularly frequent. In vitro expression 
of mutant SCN5A proteins showed that BrS mutations invariably cause a loss of sodium channel 
function at variance with the LQT3 mutation that cause an excess of sodium current. The most 
frequent biophysical mechanisms are reduced current density, slower recovery of inactivation, 
shift of voltage dependence of inactivation and an enhancement in the intermediate inactivation. 
Mutations in the SCN5A gene may also modify the interaction with the sodium channel beta-
subunit and with other proteins controlling intracellular localization of the channel. The second, 
recently  identified  BrS  gene is  called   GPD1-L,  encoding   for  the  Glycerol-3-Phosphate-
Dehydrogenase 1-like protein29. A mutation  was reported  to co-segregate  with the BrS 
phenotype in a single large family. The function of GPD1-L is poorly known at present, but 
preliminary in vitro data suggest that it controls the membrane expression of the sodium 
channels and that the mutation reduces the amount of sodium current similar to that observed for 
other BrS mutations affecting SCN5A. Quinidine, a non-specific blocker of cardiac transient 
outward current (Ito) has been proposed as gene-specific therapy for BrS. This proposal is based 
the idea that by blocking repolarizing currents, and specifically Ito, which is active during the 
initial phases of action potential, quinidine could restore the equilibrium between inward 
(constitutively reduced in BrS) and outward currents. The available clinical data show that 
quinidine prevents arrhythmia inducibility at PES and suggest a positive long-term effect in 
preventing the occurrence of spontaneous arrhythmias. Although no final proof of effectiveness 
is available quinidine may be regarded as an adjunctive therapy for patients at higher risk and to 
reduce   the   number   of   ICD   shock   in   patients   with   multiple   recurrences.  
Cardiomyopathies associated with ventricular arrhythmias                                 
Hypertrophic   Cardiomyopathy                                                                              
               Hypertrophic cardiomyopathy (HCM) is the most prevalent genetic cardiovascular 
disease affecting one in 500 individuals, and is the most common cause of sudden cardiac death 
in young athletes30. It is remarkable for its genetic and phenotypic heterogeneity and can 
manifest with negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte 
disarray, absent to severe left-ventricular outflow tract obstruction, and distinct septal contours/
morphologies such as reverse curve, sigmoidal, and apical variant-HCM. The clinical course 
also varies extremely, ranging from an asymptomatic lifelong   course   to   dyspnea/angina 
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 8(Suppl. 1): S20-S31 (2008)Maully J. Shah, “Genetics of Inherited Arrhythmias in Children”                                        S26
refractory to pharmacotherapy to sudden death as the sentinel event.                           
Genetic background of hypertrophic cardiomyopathy                                        
            Since the sentinel discovery of the first locus for familial HCM (1989) and the first 
mutations involving the MYH7-encoded beta myosin heavy chain (1990) as the pathogenic basis 
for HCM, over 300 mutations scattered among at least 24 genes encoding various sarcomeric, 
calcium-handling and mitochondrial proteins have been identified31,32. The most common 
genetically mediated form of HCM is myofilament HCM, with hundreds of disease-associated 
mutations in eight genes encoding proteins critical to the sarcomere's thick myofilament [beta-
myosin heavy chain (MYH7), regulatory myosin light chain (MYL2) and essential myosin light 
chain (MYL3)], intermediate myofilament (myosin binding protein C; MYBPC3), and thin 
myofilament [cardiac troponin T (TNNT2), alpha-tropomyosin (TPM1), cardiac troponin I 
(TNNI3),   and   actin   (ACTC)]33.   More   recently,   mutations   have   been   described   in   the 
myofilament protein alpha-myosin heavy chain encoded by MYH633. In the past, it was thought 
that specific mutations in these myofilament genes were inherently 'benign' or 'malignant', 
genotype-phenotype studies involving a large cohort of unrelated patients have indicated that 
great caution must be exercised in assigning particular prognostic significance to any particular 
mutation. Furthermore, those studies have demonstrated that the two most common forms of 
genetically   mediated   HCM,   MYH7   HCM   and   MYBPC3   HCM,   are   phenotypically 
indistinguishable34. The prevalence of mutations in the eight most common myofilament-
associated   genes,   currently   comprising   the   commercially   available   HCM   genetic   test 
(www.hpcgg.org) in different international cohorts, ranges from 30 to 61%, still leaving a large 
number of patients with genetically unexplained disease.                                               
            Over the past few years, the spectrum of HCM-associated genes expanded outside the 
myofilament to encompass additional subgroups that could be classified as 'Z-disc HCM', 
'calcium-handling HCM', and 'metabolic HCM'. As a result of its close proximity to the 
contractile apparatus of the myofilament and its specific structure-function relationship with 
regards to cyto-architecture, as well as its role in the stretch-sensor mechanism of the sarcomere, 
recent attention has been focused on the cardiac Z-disc. Initial mutations were described in 
muscle LIM protein encoded by CSRP3 and telethonin encoded by TCAP35. LDB3-encoded 
LIM   domain   binding   3,   ACTN2-encoded   alpha   actinin   2   and   VCL-encoded 
vinculin/metavinculin have recently been added to that list. Interestingly, although the first 
HCM-associated mutation in vinculin was found in the cardiac-specific insert of the gene, 
yielding the protein called metavinculin, the follow-up study also identified a mutation in the 
ubiquitously expressed protein vinculin.                                                                         
            As the critical ion in the excitation-contraction coupling of the cardiomyocyte, calcium 
and proteins involved in calcium-induced calcium release have always been of great interest in 
the pathogenesis of HCM. Although with very low frequency, mutations have been described in 
the promoter and coding-region of PLN-encoded phospholamban, an important inhibitor of 
cardiac muscle sarcoplasmic reticulum Ca2+-ATPase (SERCA) as well as in the RyR2-encoded 
cardiac ryanodine receptor36. Three novel mutations in JPH2-encoded junctophilin 2 in three, 
previously genotype-negative, patients with HCM have been recently discovered. This is the 
first time that JPH2, which is thought to play a role in approximating the sarcoplasmic reticulum 
calcium release channels and plasmalemmal L-type calcium channels, has been implicated in the 
pathogenesis   of   HCM33.                                                                              
               The last important genetic subgroup of HCM is that of metabolic HCM, involving 
mitochondrial and lysosomal proteins. In 2005, Arad and colleagues  first described mutations in 
lysosome-associated membrane protein 2 encoded by LAMP2 and protein kinase gamma-2 
encoded by PRKAG2 in glycogen storage disease-associated genes mimicking the clinical 
phenotype of HCM37. In 2005, a mutation in FXN-encoded frataxin was described in a patient 
with HCM. Although this patient also harbored a myofilament mutation in MYBPC3-encoded 
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myosin binding protein C, functional characterization showed significant influence of the FXN 
mutant on the phenotype, suggesting that the observed alterations in energetics may act in 
synergy with the present myofilament mutation. Similar to PRKAG2 and LAMP2, Fabry's 
disease can express predominant cardiac features of left ventricular hypertrophy. Over the years, 
mutations in GLA-encoded alpha-galactosidase A have been found in patients with this 
multisystem   disorder33.                                                                          
            Although up to 24 HCM susceptibility genes involving different pathways have been 
identified, the search for novel mutations in new genes continues. A genome-wide linkage study 
recently identified a new locus for HCM in a large family with left ventricular hypertrophy 
located on chromosome 7.  Subsequent studies of genes located in this region, however, have so 
far not yielded the causative gene33.                                                                                     
Genotype-phenotype correlations in hypertrophic cardiomyopathy                            
               Several   studies   have   tried   to   identify   phenotypic   characteristics   of 
myofilament/sarcomeric HCM to facilitate genetic counseling and strategically direct clinical 
genetic testing. Although several phenotype–genotype relationships have emerged to increase 
the  yield   of   genetic   testing,   these  patient   profiles   have  not  been   particularly   clinically 
informative.  Echocardiographically determined septal morphology was recently linked to the 
underlying genetic substrate in which the septal contour, classified as reverse septal contour, 
sigmoidal septal contour, apical, and neutral contour. In the early 1990s Solomon et al. described 
an early genotype-phenotype observation involving a small number of patients and family 
members, and discovered that patients with mutations in the beta myosin heavy chain (MYH7 
HCM)   generally   had   reversed   curvature   septal   contours   (reverse   curve   HCM).
            Recently, a large genotype-phenotype analysis correlating the septal morphology with 
the underlying genotype. In an analysis of the echocardiograms of 382 previously genotyped and 
published patients, it was observed that sigmoidal HCM (47% of the cohort) and reverse curve 
HCM (35% of the cohort) were the two most prevalent anatomical subtypes of HCM, and 
discovered that the septal contour was the strongest predictor of the presence of a myofilament 
mutation, regardless of age. The yield of the commercially available HCM genetic test for 
myofilament HCM was 79% in reverse curve HCM but only 8% in patients with sigmoidal 
HCM. Of the smaller subgroup of patients with apical HCM, 32% had a mutation in one of the 
myofilaments. These observations may facilitate echo-guided genetic testing by enabling 
informed genetic counseling about the a-priori probability of a positive genetic test based upon 
the patient's expressed anatomical phenotype. In addition, the paucity of myofilament mutations 
in sigmoidal HCM opens the door for research to elucidate the molecular/genetic determinants 
of   sigmoidal   HCM39.                                                                              
Arrhythmogenic right ventricular dysplasia or cardiomyopathy                                           
            Arrhythmogenic right ventricular dysplasia or cardiomyopathy (ARVD) is a heart muscle 
disease,   often   familial,   that   is   characterized   pathologically   by   atrophy   and   fibro-fatty 
replacement of the right ventricular myocardium and clinically by ventricular arrhythmias of 
right ventricular origin or sudden death39,40. The progressive loss of the RV myocardium has 
been related to a genetically determined dystrophic process, an inflammatory myocardial injury 
and death, or a programmed cell death ("apoptosis").                                                                   
            The clinical presentation of ARVD peculiarly consists of arrhythmias of right ventricular 
origin ranging from isolated premature ventricular beats to sustained ventricular tachycardia or 
ventricular fibrillation leading to sudden death. Other clinical manifestations of the disease 
include global and/or regional dysfunction and structural alterations of the right ventricle, ECG 
depolarization/repolarization changes characteristically in right precodial leads, and evolution to 
right or biventricular heart failure mimicking dilated cardiomyopathy41.                         
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Genetic   background   of   Arrhythmogenic   right   ventricular   dysplasia/cardiomyopathy
            Several loci of ARVD have been mapped. In addition to ARVD1 on 14q23-q24, these 
include ARVD2 on 1q42-q43, ARVD3 on 14q12-q22, ARVD 4 on 2q32.1-q32.3, ARVD5 on 
3p23, ARVD6 on 10p13-p12, ARVD7 on 10q22.3, ARVD 8 on 6p24, ARVD9 on 12p11, 
ARVD10 on 18q12.1-q12.2, and ARVD 11 on 18q2142. The causative gene in ARVD1 is 
TGFB3, ARVD2 is RYR2, in ARVD5 is LAMR1, in ARVD8 DSP and in ARVD9 PKP2, in 
ARVD10DSG2, and in ARVD11 DSC2.  ARVD2 is allelic with CPVT. Tiso et al suggested that 
ARVD2 associated mutations increase RYR2 mediated calcium release to the cytoplasm where 
as CPVT associated mutations do not significantly affect cytosolic calcium levels. ARVD7 is a 
type of Desmin related myopathy in which there are intrasarocplasmic aggregates of Desmin. 
Myopathy may be associated with cardiomyopathy. ARVD8 is caused by mutation in the gene 
encoding desmoplakin (DSP).  Gerull et al speculated that lack of plakophilin-2 or incorporation 
of mutant plakophilin in the cardiac desmosomes in ARVD9 impairs cell to cell contacts and as 
a   consequence   disrupts   adjacent   cardiomyocytes   in   response   to   stretch   and   stress. 
Intercellulardisruption would occur first in areas of high stress and stretch: RV outflow tract, 
apex and sub-tricuspid area (triangle of dysplasia)41. The potential for ventricular arrhythmias in 
ARVD is the intrinsic variation in conduction properties as a result of patchy areas of fibrofatty 
myocyte degeneration. The desmosomal cadherins are potential cell adhesions molecules of the 
desmosome   type   of   cell   junction.   Two   classes   have   been   identified:   desmogleins   and 
desmocollins. Mutations  in DSG2 have been correlated  with ARVD10 and DSC2 with 
ARVD1143.  
Conclusion
            Despite recent advances in the understanding of the genetic background of inherited 
arrhythmias, genetic testing is still in its infancy. In families with inherited arrhythmias, if a 
pathogenic mutation is identified by genetic testing, it becomes possible to establish a pre-
symptomatic diagnosis of the disease among other family members. In certain instances, where 
predictable genotype-phenotype correlations have been established, the results can provide 
important information to drive management or assist in reproductive counseling. As the genetic 
basis   of   arrhythmias   continues   to   unravel,   a   transition   from   reactive   and   suppressive 
management to a new paradigm of rational and pre-emptive treatment to prevent the expression 
of genetic mutations is envisioned. 
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